Establishing a definitive pathologic diagnosis in surgical
|
|
- Rosanna Pope
- 5 years ago
- Views:
Transcription
1 SPECIAL ARTICLE Best Practices in the Application of Immunohistochemistry in Urologic Pathology Report From the International Society of Urological Pathology Consensus Conference Mahul B. Amin, MD,* Jonathan I. Epstein, MD,w Thomas M. Ulbright, MD,z Peter A. Humphrey, MD, PhD,y Lars Egevad, MD,8 Rodolfo Montironi, MD,z David Grignon, MD,z Kiril Trpkov, MD,# Antonio Lopez-Beltran, MD,** Ming Zhou, MD,ww Pedram Argani, MD,w Brett Delahunt, MD,zz Daniel M. Berney, MD,yy John R. Srigley, MD,88 Satish K. Tickoo, MD,zz and Victor E. Reuter, MDzz Abstract: Members of the International Society of Urological Pathology (ISUP) participated in a half-day consensus conference to discuss guidelines and recommendations regarding best practice approaches to use of immunohistochemistry (IHC) in differential diagnostic situations in urologic pathology, including bladder, prostate, testis and, kidney lesions. Four working groups, selected by the ISUP leadership, identified several highinterest topics based on common or relevant challenging diagnostic situations and proposed best practice recommendations, which were discussed by the membership. The overall summary of the discussions and the consensus opinion forms the basis of a series of articles, one for each organ site. This Special Article summarizes the overall recommendations made by the four From the *Department of Pathology & Laboratory Medicine, Cedars- Sinai Medical Center, Los Angeles, CA; wdepartment of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD; zdepartment of Pathology, Indiana University School of Medicine, Indianapolis, IN; ydepartment of Pathology & Immunology, Washington University School of Medicine, St Louis, MO; wwdepartment of Pathology, New York University Medical Center; zzdepartment of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; 8Department of Pathology-Oncology, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, Sweden; zsection of Pathological Anatomy, Polytechnic University of the Marche Region School of Medicine, United Hospitals, Ancona, Italy; #Department of Pathology and Laboratory Medicine, University of Calgary and Calgary Laboratory Services, Calgary, AB; 88Trillium Health Partners, Mississauga and McMaster University, Hamilton, ON, Canada; **Unit of Anatomic Pathology, Department of Surgery Universidad de Cordoba, Cordoba, Spain; zzdepartment of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, Wellington, New Zealand; and yydepartment of Cellular Pathology, Centre for Molecular Oncology, Queen Mary University of London, London, UK. M.B.A and J.I.E. are joint first authors. Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Correspondence: Mahul B. Amin, MD, Department of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Suite 8707, Los Angeles, CA ( mahul.amin@ cshs.org). Copyright r 2014 by Lippincott Williams & Wilkins working groups. It is anticipated that this ISUP effort will be valuable to the entire practicing community in the appropriate use of IHC in diagnostic urologic pathology. Key Words: ISUP recommendations, immunohistochemistry, best practices, summary, prostate adenocarcinoma, urothelial carcinoma, renal cell carcinoma, germ cell tumors, sex cord-stromal tumors (Am J Surg Pathol 2014;38: ) Establishing a definitive pathologic diagnosis in surgical pathology involves integration of clinical information, gross pathology, routine microscopic findings, and ancillary studies, including immunohistochemistry (IHC). In recent years, IHC has markedly informed our practice, adding objectivity to our diagnoses. There has been an explosion of literature promulgating various new antibodies and their potential utility in diagnostic pathology. However, as with any technique, IHC has its share of pitfalls and disadvantages (clone selection, titration, validation, false positives, false negatives, etc.). Besides technical and interpretation-related (subcellular localization and pattern) deficiencies, a recurring problem remains antibody overuse that is, use of a disproportionate number of antibodies without a judiciously selected IHC panel. An important prerequisite in contemporary health care is efficient stewardship of resources and testing. The Executive Committee of the International Society of Urological Pathology (ISUP) undertook a proactive approach, with a goal to provide the best practice recommendations in the application of IHC in the diagnostic urologic pathology. Our aim was to establish guidelines and recommendations that would benefit the entire practicing community in the appropriate use of IHC in diagnostic urologic pathology. To achieve this objective, ISUP conducted a half day conference on Sunday, March 3, 2013, at the 102nd United States and Canadian Academy of Pathology (USCAP) in Baltimore. Am J Surg Pathol Volume 38, Number 8, August
2 Amin et al Am J Surg Pathol Volume 38, Number 8, August 2014 PROCESS FOR DEVELOPING THE ISUP RECOMMENDATIONS FOR BEST PRACTICES Four working groups were identified to propose best practices recommendations for the prostate, kidney, bladder, and testis organ sites. For each organ site, working group members identified and selected several high-interest topics on the basis of a particular common or relevant challenging diagnostic situation (eg, workup of atypical small acinar proliferations in the prostate or role of IHC in subtyping of germ cell tumors) or a pattern-based differential diagnostic approach (eg, IHC panel for spindle cell lesions of the bladder or IHC in the workup of renal tumors with predominantly clear cells). The proposed recommendations, on the basis of the literature review, personal professional experience, and discussions among the working group members, were presented and discussed at the conference and were subject to a vote by the ISUP members attending the conference. The consensus recommendations were accepted on the basis of a majority vote by the ISUP members attending the conference. If there were minor differences of opinion, the consensus recommendations were modified on the basis of the discussion. If no consensus was established, due to lack of published information or major differences in experience, these issues were noted as having no consensus. The moderators of the consensus conference were M.B.A. and J.I.E. The prostate working group comprised J.I.E. (Lead) and P.A.H., L.E., and R.M. The urinary bladder group consisted of M.B.A. (Lead) and D.G., K.T., and A.L.-B. The kidney working group was led by V.E.R. with P.A., B.D., and M.Z. as members of the renal IHC group. The testis working group comprised T.M.U. (Lead) and D.M.B., J.R.S., and S.K.T. B.D. recorded the minutes for the conference. TOWARD BEST PRACTICE APPROACHES IN THE APPLICATION OF IHC IN UROLOGIC PATHOLOGY Several of the working group members have made numerous observations in their clinical and consultation practices, which point to some prevalent flaws in the integration of IHC as a diagnostic adjunct. Although consult experiences are inherently skewed toward difficult or controversial cases, several recurring themes observed among such cases are noteworthy and broadly applicable irrespective of the specific diagnostic challenge to be resolved by IHC. These issues are summarized in Table 1 and are likely to be applicable to most topics covered by the various workgroups of the Consensus Conference (and, for that matter, for all surgical pathology). The optimal best practice approach is to construct an appropriate, well-balanced IHC panel on the basis of a specific differential diagnostic consideration. In keeping with this general philosophy, therefore, the approach varied between the 4 workgroups toward diagnostically challenging differentials for their organ sites. This is reflected in the overall organization and presentation of the recommendations in the TABLE 1. General for a Best Practice Approach in the Application of IHC in Urologic Pathology Observations Best Practice Approach Tendency to apply a wide array of antibodies (almost indiscriminate) to arrive at a diagnosis Serious misdiagnoses are made by inappropriate use of IHC or by incomplete knowledge of range of antibody expression Unexpected immunoreactions frequently occur Lack of attention to pattern of staining Lack of attention to controls Suboptimal blocks selected for study or incorrect areas of a section are evaluated Overall overreliance on IHC staining to arrive at the final diagnosis Construct a well-balanced IHC panel on the basis of the specific differential diagnostic situation: Do not use antibodies singly, preferably include antibodies that are expected to be positive and negative for the case Panels need to be adjusted as novel markers are reported Continuously consider discarding older antibodies, as newer more valuable antibodies are reported More is not necessarily better. If you have no idea about the diagnosis, do not stain it. Be continuously updated with the literature regarding the range of expression utility of antibodies constantly changes as new studies are published and new markers are introduced There is no perfect antibody. Sensitivity and specificity is not inherent to an antibody but varies on the basis of the diagnostic situation Antibody positivity is valuable only in the context of appropriate cellular localization (nuclear, cytoplasmic, membranous) Attention to both external and internal controls is imperative Misinterpretation may occur As different pathologies have different staining reactions Different grades or patterns may have different staining reactions Selection of the appropriate block/s containing lesional areas pertinent to the differential diagnosis is absolutely critical Diagnose every case after review of IHC only in the context of morphology and the clinical situation 4 manuscripts generated as part of each workgroup s preconference, consensus conference, and postconference deliberations. These manuscripts are published in the online-only format of this month s issue. 1 4 Whereas this Special Article provides a broad overview and summary of the ISUP recommendations made in all 4 manuscripts, each separate manuscript (bladder, prostate, kidney, and testis) contains more detailed discussion and context, references, tables, and illustrations. Summary of the Bladder Workgroup The bladder group discussed 5 topics r 2014 Lippincott Williams & Wilkins
3 Am J Surg Pathol Volume 38, Number 8, August 2014 Best Practices in IHC Applications in Urologic Pathology (A) Confirmation of urothelial differentiation at a metastatic site or in a bladder primary in a tumor with unusual histology There is no ideal marker or established panel to confirm urothelial differentiation. On the basis of the differential diagnostic consideration, positivity for GATA3, CK20, p63, and either HMWCK or CK5/6 is of value in proving urothelial differentiation in the appropriate morphologic and clinical context. Uroplakin III may be used as a second-line marker. Markers with potential utility but needing additional validation include S100P and Uroplakin II. There is limited utility for CK7 and thrombomodulin; a CK7-negative tumor is less likely to be a urothelial carcinoma (UCa). (B) Distinction of reactive atypia from carcinoma in situ It was the consensus that morphology remains the gold standard in this differential diagnosis and that, at best, the IHC panel of CK20/p53/ CD44(s) has potential utility but is variably used and has limitations. The immunostaining pattern must be interpreted with strict morphologic correlation as overreliance on IHC may be misleading, particularly in the posttreatment setting. IHC has no role in the distinction of dysplasia versus carcinoma in situ and in the grading of papillary UCa. (C) Role of IHC in staging of bladder cancer In a subset of cases, depending on the clinical and histologic context, broad-spectrum cytokeratins (to identify early or obscured invasion) and desmin (distinction of muscle from desmoplasia and to highlight muscle contours for subclassification) may have a distinct role in staging UCa. Limited experience and conflicting data preclude recommendation of use of smoothelin or vimentin for subclassifying the type of muscle at this time. (D) Distinction between spindle cell lesions of the bladder Depending on the situation, in a purely spindled proliferation and in limited specimens, if IHC is resorted to, we recommend an IHC panel of 6 markers including ALK-1, SMA, desmin, cytokeratin (AE1/AE3), and p63 with either of HMCK or CK5/6. (E) Prognostic and predictive markers in current clinical practice Currently, there are no prognostic IHC or molecular studies that are recommended to be routinely performed on biopsy or resection specimens. Summary of the Prostate Workgroup The prostate group covered 9 topics: (A) IHC panel for the diagnosis of limited adenocarcinoma in needle biopsies (i) Workup of atypical biopsies in general: Either HMWCK (34BE12 or CK5/6 or others) or p63 or a combination of the 2 with AMACR either in a double or triple cocktail is recommended for the workup of small foci of atypical glands suspicious for adenocarcinoma of the prostate. ERG is optional as it is present in only 40% to 50% of prostate cancers and also positive in high-grade prostatic intraepithelial neoplasia. In the setting of obvious carcinoma, there is no justification to perform basal cell staining and staining for AMACR. In the setting of obviously benign glands, there is no justification to perform basal cell staining and staining for AMACR. (ii) Workup of atypical foci with definite cancer in other parts: (a) Gleason score 3+4 = 7 or higher-grade cancer on at least 1 part. Is workup of other parts with atypical foci suspicious for Gleason score 3+3 = 6 cancer indicated? ISUP Recommendation: Unlikely to change clinical treatment so not recommended. (b) Gleason score 4+3 or 4+4 = 8 cancer on at least 1 part. Is workup of other parts with atypical small foci suspicious for the same-grade cancer indicated? ISUP Recommendation: The extent of high-grade cancer could affect clinical treatment such that workup of other atypical possible high-grade cancer foci is justified. (c) Gleason score 4+3 or higher-grade cancer on at least 1 part. Is workup of other parts for cribriform intraductal carcinoma as against diagnosing Gleason pattern 4 indicated, if doing so does not change the overall grade? ISUP Recommendation: Given that intraductal carcinoma in the vast majority of cases is considered an extension of high-grade cancer into prostatic ducts and acini, it is not recommended in the setting of definitive invasive high-grade cancer that workup of additional cribriform lesions be pursued. (d) Gleason score 3+3 on at least 1 part. Is workup of other parts for possible small foci of 3+3 = 6 indicated? ISUP Recommendation: The number of positive cores and/or their location could possibly affect subsequent therapy in terms of suitability for active surveillance or focal therapy, such that unless one knows with certainty that it would not affect therapy, it is justified to perform an IHC workup of additional atypical foci. (B) Poorly differentiated prostate adenocarcinoma versus UCa Option to use PSA as a first test to identify prostate adenocarcinoma (PCa) and GATA3 to identify UCa. r 2014 Lippincott Williams & Wilkins
4 Amin et al Am J Surg Pathol Volume 38, Number 8, August 2014 If GATA3 not is available, then HMWCK and p63 can be used. If the tumor is PSA positive with intense staining and HMWCK and p63 negative, the findings are diagnostic of PCa. If the tumor is equivocal/weak/negative for PSA and negative/focal for p63 and HMWCK, then P501S, NKX3.1, and GATA3 has to be used. Some experts also include PAP in this second round of staining. If the tumor is negative for PSA and diffusely strongly positive for p63 and HMWCK, the findings are diagnostic of UCa. If the tumor is negative for PSA and moderately to strongly positive for GATA3, the findings are diagnostic of UCa. Laboratories should be encouraged to use GATA3 for UCa and add P501S and NKX3.1 as prostate markers in addition to PSA, p63, and HMWCK. If GATA3, p501s, and NKX3.1 are not available in equivocal cases, they should be sent out for consultation to laboratories with these antibodies. The prostate workgroup discussed 7 other topics, which included: (C) high-grade prostatic adenocarcinoma versus bladder adenocarcinoma; (D) prostatic small cell carcinoma versus high-grade prostatic adenocarcinoma; (E) metastatic carcinoma of unknown primary rule out PCa; (F) nonspecific granulomatous prostatitis/xanthoma versus high-grade PCa; (G) adult prostate sarcoma versus sarcomatoid carcinoma of prostate; (H) colorectal adenocarcinoma versus high-grade PCa; and (I) prognostic IHC markers. Numerous tables outline the advantages and disadvantages of commonly used antibodies on the basis of the applicable ISUP recommendations for each specific diagnostic situation. These are outlined in detail in the online version of the manuscript. 2 Summary of the Testis Workgroup The testis workgroup discussed 6 topics: To resolve these differential diagnostic situations, the workgroup has presented 9 algorithms as tables with specific antibodies within each algorithm to help resolve challenging scenarios within these headings. These are outlined in detail with illustrations in the online version of the manuscript. 3 (A) The differential diagnosis of germ cell tumors A general approach to the subtyping of germ cell tumors can be achieved therefore by a limited panel consisting of antibodies directed against OCT4, CD117, CD30, and Glypican 3 (GPC3), although this may be further reduced if the light microscopic morphology is also limited to a more restricted differential. For instance, the differential diagnosis of seminoma versus embryonal carcinoma could be effectively evaluated in most cases by a 2-stain panel of CD117 and CD30. (B) The differential diagnosis of sex cord-stromal tumor and germ cell tumor A reasonable and efficient panel for the differential diagnosis of sex cord-stromal tumor versus germ cell tumor consists of SALL4, a-inhibin, and calretinin. In a laboratory lacking SALL4, an alternative, although somewhat more complex, algorithm can be devised to assist with this differential diagnosis using a panel of OCT4, GPC3, a-inhibin, and calretinin. (C) The differential diagnosis of lymphoma and germ cell tumor An efficient initial panel for the differential diagnosis of germ cell tumor and large cell lymphoma of the testis consists of SALL4, CD45, CD20, and CD3 or, in the absence of SALL4, consists of OCT4, GPC3, AE1/AE3, CD45, CD20, and CD3. (D) The differential diagnosis of metastatic carcinoma and germ cell tumor An efficient and concise initial IHC panel for the differential diagnosis of germ cell tumor versus high-grade carcinoma consists of SALL4, OCT4, and epithelial membrane antigen (EMA) or, alternatively, OCT4, GPC3, EMA, and CK7. If the diagnosis of metastatic carcinoma is supported, appropriate additional immunohistochemistry to determine the primary should be performed based on clinical information and morphology. (E) The differential diagnosis of choriocarcinoma and seminoma with syncytiotrophoblast cells This distinction can be accomplished with OCT4, which is uniformly positive in seminoma cells and negative in trophoblast cells. (F) The differential diagnosis of intratubular germ cell neoplasia and atypical intratubular germ cells OCT4 is the preferred marker because of its uniform sensitivity for IGCNU. Placental alkaline phosphatase and podoplanin are good alternative choices with a similar immunoreactivity profile. Summary of the Kidney Workgroup The kidney workgroup discussed 3 overarching topics. As there are several differential diagnostic situations, entities, and patterns in the classification of primary renal neoplasms, the workgroup has provided numerous tables in their manuscript to outline staining reactions and to support their overall recommendations. 4 (A) Markers to establish the diagnosis of renal neoplasm (site of origin) PAX8 is the most useful IHC marker for establishing the diagnosis of metastatic renal cell carcinoma (RCC). One can use IHC for other markers such as ER, CDX2, PSA, TTF-1, GATA3, and r 2014 Lippincott Williams & Wilkins
5 Am J Surg Pathol Volume 38, Number 8, August 2014 Best Practices in IHC Applications in Urologic Pathology p63 to help exclude other carcinomas, including those that also may label for PAX8. The other IHC markers currently in common practice (CD10, RCC marker antigen, Ksp-cadherin) are supportive of metastatic RCC but usually not indicated or useful. (B) Markers to aid in the classification of primary renal neoplasms (i) Tumors predominantly composed of clear cells Clear cell RCC can be distinguished from chromophobe RCC using a panel that includes CAIX, CD117, and CK7. Clear cell RCC can be distinguished from clear cell papillary RCC using a panel that includes CAIX, CK7, and racemase (AMACR). Qualitative differences in CAIX staining between the 2 entities is important to evaluate. Clear cell RCC can be distinguished from epithelioid angiomyolipoma using a panel that includes CAIX and cathepsin-k. We suggest including a wide-spectrum cytokeratin (AE1/AE3) or EMA to document the presence or absence of epithelial lineage. If the laboratory does not have cathepsin-k, the melanomaassociated markers HMB-45 and MART-1 can be used. Clear cell RCC can be distinguished from MiTF-TFE translocation associated carcinomas using a panel of antibodies that include cathepsin-k, TFE3, and TFEB. If TFE3 and TFEB are inconclusive (only weak or patchy nuclear staining or high background), fluorescence in situ hybridization assays should be performed. Epithelioid angiomyolipoma can be distinguished from MiTF-TFE translocation associated carcinoma by nuclear expression of PAX8 in the latter and total absence of CAIX and epithelial differentiation (AE1/ AE3, EMA) in the former. (ii) Tumors with a significant papillary component Special attention should be paid to areas of the tumor that transition from low grade to high grade. Proper prosecting can help select key diagnostic areas. A panel that includes CAIX, CK7, and racemase (AMACR) can discriminate between clear cell RCC with papillary areas and papillary RCC. This same panel can be used to distinguish clear cell RCC from true papillary RCC and clear cell papillary RCC. Type 2 papillary RCC is likely a heterogenous group of tumors that usually stain for racemase but may exhibit variable results with CK7, including total lack of staining. Before this diagnosis is rendered, other specific entities should be considered in the differential diagnosis. MiTF/TFE translocation associated carcinomas may have a prominent papillary component. Cathepsin-K shows diffuse immunoreactivity in most variants except t(x;17), whereas epithelial markers are usually negative. Antibodies directed toward the TFE3 and TFEB proteins are highly specific but somewhat unreliable, so break-apart fluorescence in situ hybridization probes directed against these gene fusions are better. A subset of these tumors will exhibit immunoreactivity with melanocytic markers (HMB-45 and MART-1). (iii) Tumors with extensive cytoplasmic eosinophilia Distinguishing oncocytoma from an eosinophilic variant of chromophobe RCC is the most common diagnostic challenge for which close attention to nuclear cytology and cytoplasmic features can be supplemented by performing IHC staining for CK7. Laboratories that have Ksp-cadherin may find this marker useful, although qualitative rather than quantitative differences in staining must be taken into account. S100A1 is potentially a very useful marker, which needs further validation. Oncocytic papillary RCC is a rare diagnosis that does not require IHC for proper classification. Oncocytic AML will express melanocytic markers and cathepsin-k. (iv) Tumors with a predominant sarcomatoid pattern of growth Careful prosecting and attention to areas of morphologic transition can aid in establishing a proper diagnosis and choosing the most appropriate section(s) to perform ancillary studies. Vimentin and PAX8 are unlikely to contribute significantly to the diagnosis, although PAX8 can narrow down the diagnosis to either renal or urothelial origin, ruling out metastatic disease. In combination with other markers, CAIX may help in classifying a tumor as a clear cell RCC, but interpretation must be performed carefully. Traditional markers of urothelial lineage but not PAX8 can help identify a sarcomatoid UCa. If sarcoma enters in the differential diagnosis, the possibility of leiomyosarcoma and dedifferentiated liposarcoma can be ruled out by performing appropriate staining studies. (v) Tumors with morphology suggestive of the distal nephron origin collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) CDC, on the basis of limited data, can be distinguished from RMC using a panel that includes INI-1 and OCT4, taking into consideration the clinical history of sickle cell trait. Cytokeratin 34bE12 may be expressed in CDC but not in RMC. UCa can be distinguished from both CDC and RMC using a panel that includes GATA3 and p63 (clone 4A4). (vi) RCC, unclassified type This category should only been used when all efforts to place the tumor into a distinct entity have been exhausted or when the immunophenotype is entirely at odds with the morphologic impression. r 2014 Lippincott Williams & Wilkins
6 Amin et al Am J Surg Pathol Volume 38, Number 8, August 2014 The antibody panel used will depend on the entities being considered in the differential diagnosis. (C) Prognostic and predictive markers in renal neoplasms There are no markers or sets of markers ready for routine clinical use. Novel markers have been recently described that are associated with highrisk pathologic features and disease progression. However, these should not be used routinely until further clinical and technical validation is performed. Summary The proceedings, outcome, and recommendations of the 4 workgroups with specific ISUP recommendations form the basis of the 4 manuscripts accompanying this editorial, which are published in the online version of the manuscript. The aim is to provide relevant and succinct information of practical value to surgical pathologists to assist in their routine daily practice. For the pathologists in the United States, these recommendations have additional significance given the recent stance by the Centers for Medicare and Medicaid Services (CMS), the major payor for medical services, to reduce reimbursement for IHC. Such developments call for further scrutiny by all of us to achieve greater efficiency through implementation of best practice approaches to IHC in our continuous quest to arrive at precise and correct diagnoses for our patients. REFERENCES 1. Amin MB, Trpkov K, Lopez-Beltran A, et al. Best practices recommendations in the application of immunohistochemistry in the bladder lesions report from the International Society of Urologic Pathology Consensus Conference. Am J Surg Pathol. 2014;38:e20 e Epstein JI, Egevad L, Humphrey PA, et al. Best practices recommendations in the application of immunohistochemistry in the prostate report from the International Society of Urologic Pathology Consensus Conference. Am J Surg Pathol. 2014;38:e6 e9. 3. Reuter VE, Argani P, Zhou M, et al. Best practices recommendations in the application of immunohistochemistry in the kidney tumors report from the International Society of Urologic Pathology Consensus Conference. Am J Surg Pathol. 2014;38:e35 e Ulbright TM, Tickoo SK, Berney DM, et al. Best practices recommendations in the application of immunohistochemistry in testicular tumors report from the International Society of Urological Pathology Consensus Conference. AmJSurgPathol. 2014;38:e50 e r 2014 Lippincott Williams & Wilkins
IMMUNOPROFILES OF THE MAJOR RENAL NEOPLASMS (%staining)
Stain Clear Cell Papillary IMMUNOPROFILES OF THE MAJOR RENAL NEOPLASMS (%staining) Chromophobe Collecting Duct Carcinom a Sarcomatoid Xp11 Translocat ion Dr Jon Oxley See also www.jonoxley.com Page 1 MTSCC
More informationBEST PRACTICES IN THE APPLICATION OF IMMUNOHISTOCHEMISTRY TO DIAGNOSTIC UROLOGIC PATHOLOGY: LESSONS FROM USES & ABUSES
BEST PRACTICES IN THE APPLICATION OF IMMUNOHISTOCHEMISTRY TO DIAGNOSTIC UROLOGIC PATHOLOGY: LESSONS FROM USES & ABUSES Mahul B. Amin Professor & Chairman Department of Pathology & Laboratory Medicine Cedars-Sinai
More informationRenal tumours: use of immunohistochemistry & molecular pathology. Dr Lisa Browning John Radcliffe Hospital Oxford
Renal tumours: use of immunohistochemistry & molecular pathology Dr Lisa Browning John Radcliffe Hospital Oxford Renal tumours: the use of immunohistochemistry & molecular pathology Classification of RCC
More informationSynonyms. Nephrogenic metaplasia Mesonephric adenoma
Nephrogenic Adenoma Synonyms Nephrogenic metaplasia Mesonephric adenoma Definition Benign epithelial lesion of urinary tract with tubular, glandular, papillary growth pattern Most frequently in the urinary
More informationARTHUR PURDY STOUT SOCIETY COMPANION MEETING: DIFFICULT NEW DIFFERENTIAL DIAGNOSES IN PROSTATE PATHOLOGY. Jonathan I. Epstein.
1 ARTHUR PURDY STOUT SOCIETY COMPANION MEETING: DIFFICULT NEW DIFFERENTIAL DIAGNOSES IN PROSTATE PATHOLOGY Jonathan I. Epstein Professor Pathology, Urology, Oncology The Reinhard Professor of Urological
More information2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE. Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, CT
2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE Peter A. Humphrey, MD, PhD Yale University School of Medicine New Haven, CT 2016 WHO CLASSIFICATION OF TUMOURS OF THE PROSTATE AUTHORS : PROSTATE CHAPTER
More informationAccording to the original drawing of D. F. Gleason,
ORIGINAL ARTICLE Grading of Invasive Cribriform Carcinoma on Prostate Needle Biopsy An Interobserver Study among Experts in Genitourinary Pathology Mathieu Latour, MD,* Mahul B. Amin, MD,y Athanase Billis
More informationPathology Mystery and Surprise
Pathology Mystery and Surprise Tim Smith, MD Director Anatomic Pathology Medical University of South Carolina Disclosures No conflicts to declare Some problem cases Kidney tumor Scalp tumor Bladder tumor
More informationDiagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018
Diagnostic accuracy of percutaneous renal tumor biopsy May 10 th 2018 Dr. Tzahi Neuman Dep.Of Pathology Hadassah Medical Center Jerusalem, Israel, (tneuman@hadassah.org.il) Disclosure: 1 no conflicts of
More informationDIAGNOSTIC SLIDE SEMINAR: PART 1 RENAL TUMOUR BIOPSY CASES
DIAGNOSTIC SLIDE SEMINAR: PART 1 RENAL TUMOUR BIOPSY CASES Dr. Andrew J. Evans MD, PhD, FACP, FRCPC Consultant in Genitourinary Pathology University Health Network, Toronto, ON Case 1 43 year-old female,
More informationCoordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma
Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,
More informationACCME/Disclosures. Cribriform Lesions of the Prostate. Case
Cribriform Lesions of the Prostate Ming Zhou, MD, PhD Departments of Pathology and Urology New York University Langone Medical Center New York, NY Ming.Zhou@NYUMC.ORG ACCME/Disclosures The USCAP requires
More informationPathology of the Prostate. PathoBasic Tatjana Vlajnic
Pathology of the Prostate PathoBasic 24.01.17 Tatjana Vlajnic Overview Adenocarcinoma of the prostate Grading Special variants Mimickers of prostate adenocarcinoma Atrophy Inflammatory conditions Granulomatous
More informationRENAL EPITHELIAL NEOPLASMS: IS THERE A ROLE OF IMMUNOSTAINS IN DIAGNOSIS?
RENAL EPITHELIAL NEOPLASMS: IS THERE A ROLE OF IMMUNOSTAINS IN DIAGNOSIS? John C. Cheville, M.D. Mayo Clinic and Mayo Foundation Rochester, MN The majority of renal epithelial neoplasms are diagnosed on
More informationAlthough current American Cancer Society guidelines
ORIGINAL ARTICLE Diffuse Adenosis of the Peripheral Zone in Prostate Needle Biopsy and Prostatectomy Specimens Tamara L. Lotan, MD* and Jonathan I. Epstein, MD*w z Abstract: We have observed a group of
More informationDifferential diagnosis of HCC
Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis
More informationDisclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1
Disclosure Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-1 Case Presentation A 43 year old male, with partial nephrectomy for a right kidney mass 2013 MFMER slide-2 2013
More informationThe Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation
The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors
More informationIntraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance
& 2006 USCAP, Inc All rights reserved 0893-3952/06 $30.00 www.modernpathology.org Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance Charles C Guo 1 and
More informationProstate Immunohistochemistry. Literature Interpretation: Caveats. Must be aware of staining pattern of antibody in the relevant tissue
IHC Interpretation: General Principles (1) Prostate Immunohistochemistry Murali Varma Cardiff, UK wptmv@cf.ac.uk Sarajevo Nov 2013 Must be aware of staining pattern of antibody in the relevant tissue Nuclear/cytoplasmic/membranous
More informationPROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA AND IMPORTANT MIMICKERS PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA
PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA AND IMPORTANT MIMICKERS PROSTATIC ADENOCARCINOMA: DIAGNOSTIC CRITERIA 1 A good H & E helps! ADENOCARCINOMA DIAGNOSTIC CRITERIA Relatively uniform proliferation
More informationAlthough partial atrophy is one of the most common
ORIGINAL ARTICLE Partial Atrophy on Prostate Needle Biopsy Cores: A Morphologic and Immunohistochemical Study Wenle Wang, MD, PhD,* Xinlai Sun, MD,w and Jonathan I. Epstein, MD*zy Abstract: Partial atrophy
More informationImmunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD
Immunohistochemistry in Bone and Soft Tissue Tumors Sahar Rassi Zankoul, MD Introduction Bone tumors represent a wide variety of tumors of various origins and malignant potentials. These different tumor
More informationINTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein
INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic
More informationUpdates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency
Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency World Health Organization Available in Feb 2016 Frame work for reporting Major contributing
More informationEnterprise Interest Nothing to declare
Enterprise Interest Nothing to declare Biopsy diagnosis of renal tumors. Current applications Ondřej Hes Department of Pathology Charles University and University Hospital Plzeň Czech Republic Dealing
More informationPSA. HMCK, p63, Racemase. HMCK, p63, Racemase
Case 1 67 year old male presented with gross hematuria H/o acute prostatitis & BPH Urethroscopy: small, polypoid growth with a broad base emanating from the left side of the verumontanum Serum PSA :7 ng/ml
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationImmunohistochemistry and Bladder Tumours
Immunohistochemistry and Bladder Tumours Dr. Andrew J. Evans MD PhD FRCPC Consultant in Genitourinary Pathology University Health Network Toronto, ON Objec ves Review markers of urothelial differen a on
More informationProstatic ductal adenocarcinoma is a subtype of
ORIGINAL ARTICLE High-grade Prostatic Intraepithelial Neoplasialike Ductal Adenocarcinoma of the Prostate: A Clinicopathologic Study of 28 Cases Fabio Tavora, MD* and Jonathan I. Epstein, MD*w z Abstract:
More informationThe Role of the Pathologist Active Surveillance for Prostate Cancer
The Role of the Pathologist Active Surveillance for Prostate Cancer Thomas M. Wheeler, M.D. W. L. Moody, Jr., Professor and Chair Department of Pathology & Immunology Baylor College of Medicine Houston,
More information5/21/2018. Prostate Adenocarcinoma vs. Urothelial Carcinoma. Common Differential Diagnoses in Urological Pathology. Jonathan I.
Common Differential Diagnoses in Urological Pathology Jonathan I. Epstein Prostate Adenocarcinoma vs. Urothelial Carcinoma 1 2 NKX3.1 NKX3.1 3 4 5 6 Proposed ISUP Recommendations Option to use PSA as a
More informationROLE OF PROSTATIC BASAL CELL MARKER IN DIAGNOSIS OF PROSTATIC LESIONS
Original Research Article Pathology International Journal of Pharma and Bio Sciences ISSN 0975-6299 ROLE OF PROSTATIC BASAL CELL MARKER IN DIAGNOSIS OF PROSTATIC LESIONS SUBATHRA K* Department of pathology,
More informationCollecting duct carcinoma versus renal medullary carcinoma: An appeal for nosologic and biological clarity
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2014 Collecting duct carcinoma versus renal medullary carcinoma: An appeal
More informationMale Genital Cancers in the US in Frequency of Types
Germ Cell Tumors of the Testis Pathology, Immunohistochemistry, and the Often Confusing Appearance of Their Metastases Charles Zaloudek, MD Department of Pathology UCSF Male Genital Cancers in the US in
More informationNEW IHC A n t i b o d i e s
NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology
More informationGleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA
Gleason Scoring System 2017 JASREMAN DHILLON, MD ASSOCIATE PROFESSOR, DEPARTMENT OF ANATOMIC PATHOLOGY, MOFFITT CANCER CENTER, TAMPA, FLORIDA Learners Objectives u Latest changes per ISUP 2014 that impact
More informationINTERPRETATION OF IMMUNOHISTOCHEMICAL STAINS - DIFFICULTIES AND PITFALLS. Gabor Fischer Diagnostic Services Manitoba University of Manitoba
INTERPRETATION OF IMMUNOHISTOCHEMICAL STAINS - DIFFICULTIES AND PITFALLS Gabor Fischer Diagnostic Services Manitoba University of Manitoba IHC INTERPRETATIONS LOCAL DATA Diagnostic Services Manitoba Number
More information5/21/2018. Difficulty in Underdiagnosing Prostate Cancer. Diagnosis of Prostate Cancer. Evaluation of Prostate Cancer and Atypical on Needle Biopsy
Evaluation of Prostate Cancer and Atypical on Needle Biopsy Jonathan I. Epstein Difficulty in Underdiagnosing Prostate Cancer Limited tissue on needle biopsy (1 cm. x
More informationTesticular Germ Cell Tumors; A Simplistic Approach
Testicular Germ Cell Tumors; A Simplistic Approach Merce Jorda, MD, PhD, MBA Professor and Vice Chair, Director of Anatomic Pathology Director of Genitourinary Pathology Service Interim Director of Cytopathology
More information3/28/2017. Disclosure of Relevant Financial Relationships. GU Evening Subspecialty Case Conference. Differential Diagnosis:
GU Evening Subspecialty Case Conference Rajal B. Shah, M.D. VP, Medical Director, Urologic Pathology Miraca Life Sciences, Irving, Texas Clinical Associate Professor of Pathology Baylor College of Medicine,
More informationGross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of
Tiền liệt tuyến Tiền liệt tuyến Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of solid and microcystic areas.
More informationMesothelioma: diagnostic challenges from a pathological perspective. Naseema Vorajee August 2016
Mesothelioma: diagnostic challenges from a pathological perspective Naseema Vorajee August 2016 Naseema.vorajee@nhls.ac.za Pleural diseases (whether neoplastic, reactive or infective) may have similar
More information57th Annual HSCP Spring Symposium 4/16/2016
An Unusual Malignant Spindle Cell Lesion to Involve the Breast Erinn Downs-Kelly, D.O. Associate Professor of Pathology University of Utah & ARUP Laboratories No disclosures Case 39 y/o female with no
More informationCase 1 PLEASE TURN OFF YOUR CELL PHONES 3/28/2017. Disclosure of Relevant Financial Relationships. Disclosure of Relevant Financial Relationships
PLEASE TURN OFF YOUR CELL PHONES Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME disclose
More informationDisclosure of Relevant Financial Relationships
Evening Specialty Conference - Genitourinary Pathology Case 2 Disclosure of Relevant Financial Relationships Sean R Williamson, MD Henry Ford Health System, Detroit, MI @Williamson_SR USCAP requires that
More informationProstate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
More informationGrading Prostate Cancer: Recent Changes and Refinements
USPSTF: 2012 Report on serum PSA Screening Recommendation rating of D Reduced screening, Reduced biopsies, reduced incidence Refinements currently occurring in 2017. WHY? Grading Prostate Cancer: Recent
More informationKidney, Bladder and Prostate Neoplasia. David Bingham MD
Kidney, Bladder and Prostate Neoplasia David Bingham MD typical malignant cytology of bladder washings 1 benign 2 malignant typical malignant cytology of bladder washings b Bladder tumor Non invasive papillary
More informationVarious hereditary, acquired and neoplastic conditions can lead to cyst formation in the kidney.
Dr. Fatima AlAl-Hashimi Hashimi,, MD, FRCPath Salmaniya Medical Complex, Bahrain Various hereditary, acquired and neoplastic conditions can lead to cyst formation in the kidney. The most frequently encountered
More informationThe role of immunohistochemistry in surgical pathology of the uterine corpus and cervix
The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
More informationHistopathological diagnosis of CUP
Histopathological diagnosis of CUP Dr Karin Oien karin.oien@glasgow.ac.uk Disclosure slide Dr Karin Oien has no financial interests in any company mentioned in this presentation. Dr Karin Oien is conducting
More informationACCME/Disclosures. M31078/07 Ondřej Hes 4/13/2016
M31078/07 Ondřej Hes Department of Pathology Charles University and University Hospital Plzeň Bioptická laboratoř Plzeň Czech Republic ACCME/Disclosures The USCAP requires that anyone in a position to
More informationACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016
Diagnosing Mesothelioma in Limited Tissue Samples Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016 Sanja Dacic, MD, PhD University of Pittsburgh ACCME/Disclosures GENERAL RULES
More informationProstate Pathology: Prostate Carcinoma, variants and Gleason Grading (Part 1)
Prostate Pathology: Prostate Carcinoma, variants and Gleason Grading (Part 1) Jae Y. Ro, MD, PhD June 7, 2012 Ten Leading Cancer Types for the Estimated New Cancer Cases and Deaths By Sex, United States,
More information4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD
MUSC Pathology Symposium Kiawah Island April 18, 2018 Jesse K. McKenney, MD 1 Urothelial Carcinoma with Alternative Differentiation 2 Urothelial Carcinoma with Alternative Differentiation Recognition as
More information05/07/2018. Types of challenges. Challenging cases in uterine pathology. Case 1 ` 65 year old female Post menopausal bleeding Uterine Polyp
Types of challenges Challenging cases in uterine pathology Nafisa Wilkinson Gynaecological Pathologist UCLH London Lack of complete history often, NO clinical history at all! Cases from other centres often
More informationThe International Society of Urological Pathology Companion Meeting
The International Society of Urological Pathology Companion Meeting 2016 1 2 PROSTATE EXPERT PANEL Lars Egevad (Panel Leader) Dan Berney David Bostwick Eva Comperat Brett Delahunt Andrew Evans Samson Fine
More information3/23/2017. Significant Changes in Prostate Cancer Classification, Grading, Staging and Reporting. Disclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships Staging and Reporting of Prostate Cancer: Major Changes in 8 th Edition AJCC Staging and CAP Cancer Checklists USCAP requires that all planners (Education
More informationClassification (1) Classification (3) Classification (2) Spindle cell lesions. Spindle cell lesions of bladder (Mills et al.
Non-epithelial tumours and nonepithelial tumour-like lesions of the bladder Dr Jonathan H Shanks The Christie NHS Foundation Trust, Manchester, UK Classification (1) Myofibroblastic proliferations and
More informationTOPICS FOR DISCUSSION
INTERNATIONAL SOCIETY OF UROLOGIC PATHOLOGY PATHOLOGIC STAGING OF SELECT UROLOGIC MALIGNANCIES Mahul B. Amin, MD Professor and Chairman Pathology and Laboratory Medicine Cedars-Sinai Medical Center Los
More informationDiagnosis, pathology and prognosis including variant pathology
PROSTATE CANCER Diagnosis, pathology and prognosis including variant pathology No Conflict of Interest Universitat Autónoma de Barcelona F.Algaba Section of Pathology PROSTATE CANCER Diagnosis, pathology
More informationBreast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases
Adrenal cortical carcinoma Inhibin Synap Melan-A Calretinin Vimentin Chromogr CK7 CK20 Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2
More informationMucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging
More informationPapillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.
Papillary Lesions of the Breast A Practical Approach to Diagnosis (Arch Pathol Lab Med. 2016;140:1052 1059; doi: 10.5858/arpa.2016-0219-RA) Papillary lesions of the breast Span the spectrum of benign,
More informationProtocol for the Examination of TURP Specimens From Patients With Carcinoma of the Prostate Gland
Protocol for the Examination of Specimens From Patients With Carcinoma of the Prostate Gland Version: Prostate 4.0.4.0 Protocol Posting Date: February 2019 Accreditation Requirements The use of this protocol
More informationUrinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
More informationImmunohistochemical Evaluation of Necrotic Malignant Melanomas
Anatomic Pathology / EVALUATION OF NECROTIC MALIGNANT MELANOMAS Immunohistochemical Evaluation of Necrotic Malignant Melanomas Daisuke Nonaka, MD, Jordan Laser, MD, Rachel Tucker, HTL(ASCP), and Jonathan
More informationThey Do Look Alike : Mimics of Prostate Cancer in Biopsy Samples
They Do Look Alike : in Biopsy Samples Gladell P. Paner, MD Departments of Pathology and Surgery (Urology) University of Chicago, IL USA Gladell.paner@uchospitals.edu Benign in Needle Biopsy 1. Benign
More informationDiagnostic Utility of Immunohistochemical Markers in Prostate Cancer
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 3 Ver. IX (March. 2017), PP 22-28 www.iosrjournals.org Diagnostic Utility of Immunohistochemical
More informationImmunohistochemical Diagnosis of Renal Neoplasms. Luan D. Truong, MD; Steven S. Shen, MD, PhD
Immunohistochemical Diagnosis of Renal Neoplasms Luan D. Truong, MD; Steven S. Shen, MD, PhD N Context. Histologic diagnosis of renal neoplasm is usually straightforward by routine light microscopy. However,
More informationDATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #2006-01 CATEGORY: CLARIFICATION SUBJECT: RESCINDMENT - DSQC MEMORANDUM 2002-08 Coding Complex Morphologic Diagnoses (revised 8/02) EFFECTIVE: For Cases
More informationCase presentations 04/10/ th Annual Seminar in Pathology Pittsburgh, PA, April 26-29, 2018
25th Annual Seminar in Pathology Pittsburgh, PA, April 26-29, 2018 Case presentations Kiril Trpkov, MD FRCPC Department of Pathology and Laboratory Medicine kiril.trpkov@cls.ab.ca 45 y/o male, pink tumor,
More informationUpdate on Thyroid FNA The Bethesda System. Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center
Update on Thyroid FNA The Bethesda System Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center Thyroid Nodules Frequent occurrence Palpable: 4-7% of adults Ultrasound: 10-31% Majority benign
More informationDivision of Oncology, S Orsola-Malpighi Hospital, Bologna, Italy. Department of Surgery, Cordoba University Medical School, Cordoba, Spain
Prostate cancer glands with cribriform architecture and with glomeruloid features should be considered as Gleason pattern 4 and not pattern 3 Daniele Minardi,1, Roberta Mazzucchelli,, Marina Scarpelli,
More informationReporting of carcinoma of unknown primary tumour (CUP)
Reporting of carcinoma of unknown primary tumour (CUP) Prof John Schofield Kent Oncology Centre with grateful thanks to Dr Karin Oien University of Glasgow Royal College of Pathologists Cancer datasets
More informationA 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy.
November 2015 Case of the Month A 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy. Contributed by: Rasha Salama, M.D., IU Department of Pathology and Laboratory Medicine
More informationBLADDER CANCER EPIDEMIOLOGY
BLADDER CANCER WHAT IS NEW AND CLINICALLY RELEVANT Canadian Geese - Geist Reservoir (my backyard), Indianapolis, USA BLADDER CANCER EPIDEMIOLOGY Urinary bladder 17,960 2% Urinary bladder 4,390 1.6% Siegel
More informationRenal Masses in Patients with Known Extrarenal Primary Primary Cancer Primary Primary n Met Mets s RCC Beni L mphoma Lung Breast Others
The Importance of Stuart G. Silverman, MD, FACR Professor of Radiology Harvard ard Medical School Director, Abdominal Imaging and Intervention Brigham and Women s Hospital Boston, MA The Importance of
More information2 to 3% of All New Visceral Cancers Peak Incidence is 6th Decade M:F = 2:1 Grossly is a Bright Yellow, Necrotic Mass with a Pseudocapsule
GENITOURINARY PATHOLOGY Kathleen M. O Toole, M.D. Renal Cell Carcinoma 2 to 3% of All New Visceral Cancers Peak Incidence is 6th Decade M:F = 2:1 Grossly is a Bright Yellow Necrotic Mass Grossly is a Bright
More informationProtocol for the Examination of Lymphadenectomy Specimens From Patients With Malignant Germ Cell and Sex Cord-Stromal Tumors of the Testis
Protocol for the Examination of Specimens From Patients With Malignant Germ Cell and Sex Cord-Stromal Tumors of the Testis Version: Testis 4.0.1.1 Protocol Posting Date: February 2019 Accreditation Requirements
More informationPathology of Renal Neoplasms: Recent Advances
Pathology of Renal Neoplasms: Recent Advances Jae Y. Ro, M.D., Ph.D. The Methodist Hospital Weill Medical College of Cornell University, MD Anderson Cancer Center, Houston, Texas Ewha Womans University
More informationJason C Carvalho, 1 Dafydd G Thomas, 1 Jonathan B McHugh, 1 Rajal B Shah 2 & Lakshmi P Kunju 1
Histopathology 2012, 60, 597 608. DOI: 10.1111/j.1365-2559.2011.04093.x p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from
More informationFrom Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport
From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology Songlin Zhang, MD, PhD LSUHSC-Shreveport I have no Conflict of Interest. FNA on Lymphoproliferative
More informationI have nothing to disclose
A 47 year old female with multiple lung nodules Disclosure of Relevant Financial Relationships Tamar Giorgadze, MD, PhD Professor of Pathology Medical College of Wisconsin Milwaukee, Wisconsin USCAP requires
More informationImmunoexpression of napsin a in renal neoplasms
Zhu et al. Diagnostic Pathology (2015) 10:4 DOI 10.1186/s13000-015-0242-z RESEARCH Open Access Immunoexpression of napsin a in renal neoplasms Bing Zhu, Stephen M Rohan and Xiaoqi Lin * Abstract Background:
More informationProstate Biopsy Interpretation: An Illustrated Guide
Prostate Biopsy Interpretation: An Illustrated Guide Authors Prostate Biopsy Interpretation: An Illustrated Guide Rajal B. Shah, M.D. Director, Urologic Pathology Caris Life Sciences 6655 North MacArthur
More informationEnterprise Interest Nothing to declare
Enterprise Interest Nothing to declare Diagnoses one would not like to miss in soft tissue pathology early in your career Marta Sbaraglia, MD Department of Pathology Hospital of Treviso University of Padua
More informationUropathology January Jon Oxley
Uropathology January 2012 Jon Oxley Background to seminar These slides were available to view via the web from scanned slides The junior pathologists answered questions on them via the web The answers
More informationSelect problems in cystic pancreatic lesions
Disclosure Select problems in cystic pancreatic lesions Five Prime Therapeutics shareholder Adicet Bio shareholder Bristol-Meyer Squibb advisory board grace.kim@ucsf.edu Pancreatic cystic lesions Intraductal
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationDisclosures. Parathyroid Pathology. Objectives. The normal parathyroid 11/10/2012
Disclosures Parathyroid Pathology I have nothing to disclose Annemieke van Zante MD/PhD Assistant Professor of Clinical Pathology Associate Chief of Cytopathology Objectives 1. Review the pathologic features
More informationBiopsy Interpretation of Spindle cell proliferations of the Serosa
Biopsy Interpretation of Spindle cell proliferations of the Serosa Richard Attanoos, Cardiff. U.K. Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee)
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationCK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens With Equivocal Atypia. Correlation With Outcomes
CK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens With Equivocal Atypia Correlation With Outcomes Javier A. Arias-Stella III, MD; Alpa B. Shah, MD, MPH; Nilesh S. Gupta, MD;
More informationPatient identifiers Date of request Accession/Laboratory number. CLINICAL STAGE (Note 3)
Prostate Core Needle Biopsy Histopathology Reporting Guide Part 1 - Clinical Information/Specimen Receipt Family/Last name Given name(s) Date of birth DD MM YYYY Patient identifiers Date of request Accession/Laboratory
More informationRENAL NEOPLASMS: NEW ENTITIES & DIFFICULT DIAGNOSES
RENAL NEOPLASMS: NEW ENTITIES & DIFFICULT DIAGNOSES Cristina Magi-Galluzzi, MD, PhD Professor of Pathology Director of Anatomic Pathology Kidney Tumors American Cancer Society Cancer Facts and Figures
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More informationRENAL EPITHELIAL TUMORS 2009: THE ROLE OF ELECTRON MICROSCOPY IN UNDERSTANDING PATHOGENESIS, DIAGNOSIS, AND CLASSIFICATION.
RENAL EPITHELIAL TUMORS 2009: THE ROLE OF ELECTRON MICROSCOPY IN UNDERSTANDING PATHOGENESIS, DIAGNOSIS, AND CLASSIFICATION. Guillermo A. Herrera MD Nephrocor, Tempe, Arizona Epithelial renal cell tumors
More information